The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma
Glioblastoma (GBM) is the most common malignant primary brain tumor and confers a dismal prognosis. With only two FDA-approved therapeutics showing modest survival gains since 2005, there is a great need for the development of other disease-targeted therapies. Due, in part, to the profound immunosup...
Main Authors: | Bryan J. Neth, Mason J. Webb, Ian F. Parney, Ugur T. Sener |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/4/1134 |
Similar Items
-
Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma
by: Mason J. Webb, et al.
Published: (2023-05-01) -
Chimeric Antigen Receptor T Cells in Glioblastoma—Current Concepts and Promising Future
by: Rebecca Kringel, et al.
Published: (2023-07-01) -
Atypical clinical presentation of glioblastoma mimicking autoimmune meningitis in an adult
by: Angelika Stapińska-Syniec, et al.
Published: (2022-06-01) -
Immunotherapeutic Approaches for Glioblastoma Treatment
by: Nasser K. Yaghi, et al.
Published: (2022-02-01) -
The STAT3-Regulated Autophagy Pathway in Glioblastoma
by: Ronald Nicholas Laribee, et al.
Published: (2023-04-01)